Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2003 Oct;78(3):233-40.
doi: 10.1007/BF02983800.

Effects of the tyrosine kinase inhibitor imatinib mesylate on a Bcr-Abl-positive cell line: suppression of autonomous cell growth but no effect on decreased adhesive property and morphological changes

Toshio Nishihara  1 , Yasuo Miura, Yumi Tohyama, Chisato Mizutani, Terutoshi Hishita, Satoshi Ichiyama, Takashi Uchiyama, Kaoru Tohyama
Affiliations

Effects of the tyrosine kinase inhibitor imatinib mesylate on a Bcr-Abl-positive cell line: suppression of autonomous cell growth but no effect on decreased adhesive property and morphological changes

Toshio Nishihara et al. Int J Hematol. 2003 Oct.

Abstract

Expression of the Bcr-Abl oncoprotein alters various aspects of hematopoietic cells. We investigated the effects of a Bcr-Abl tyrosine kinase inhibitor, imatinib mesylate, on the proliferation, adhesive properties, and morphology of a Bcr-Abl-transferred cell line, TF-1 Bcr-Abl, in comparison with parental TF-1. First, the factor-independent growth of TF-1 Bcr-Abl was inhibited in the presence of imatinib mesylate, but this inhibition was overcome by addition of exogenous granulocyte-macrophage colony-stimulating factor. Imatinib mesylate remarkably reduced tyrosine phosphorylation of Bcr-Abl, Cbl, and Crkl in a time-dependent manner, and their complex formation also was affected. Imatinib mesylate inhibited activation of Stat5 rather than the MEK-ERK1/2 pathway. TF-1 Bcr-Abl cells exhibited a round shape, unlike TF-1, and the adhesive property to fibronectin was much lower than that of TF-1. Although the Bcr-Abl oncoprotein may be involved negatively in cell adhesion, the decreased adhesion and altered morphology of TF-1 Bcr-Abl cells were minimally affected by imatinib mesylate and seemed independent of Bcr-Abl kinase activity. The present data indicated that the Bcr-Abl-specific kinase inhibitor cannot control Bcr-Abl-induced cell alterations other than autonomous growth.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

References

    1. J Biol Chem. 1997 Jun 27;272(26):16170-5 - PubMed
    1. Blood. 1995 Jul 15;86(2):726-36 - PubMed
    1. J Biol Chem. 1997 May 30;272(22):14320-6 - PubMed
    1. Int J Hematol. 2001 Apr;73(3):278-91 - PubMed
    1. Exp Hematol. 1995 Oct;23(11):1153-9 - PubMed

Publication types

MeSH terms

LinkOut - more resources

  NODES
twitter 2